PDS Biotechnology Corp (PDSB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has a cash flow conversion efficiency ratio of 0.780x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.79 Million) by net assets ($-3.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PDS Biotechnology Corp market capitalisation for the company's overall valuation and market capitalisation.
PDS Biotechnology Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PDS Biotechnology Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PDS Biotechnology Corp ranked by their cash flow conversion efficiency. Explore PDS Biotechnology Corp (PDSB) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trust Stamp Inc
NASDAQ:IDAI
|
-0.464x |
|
FIREBIRD METALS LTD
F:7Y2
|
N/A |
|
Mycron Steel Bhd
KLSE:5087
|
0.016x |
|
Hateks Hatay Tekstil Isletmeleri AS
IS:HATEK
|
-0.099x |
|
Step One Clothing Ltd
AU:STP
|
-0.118x |
|
Metalliance SA
PA:MLETA
|
N/A |
|
MyTech Group Bhd
KLSE:7692
|
0.134x |
|
Ark Mines Ltd
AU:AHK
|
-0.048x |
Annual Cash Flow Conversion Efficiency for PDS Biotechnology Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of PDS Biotechnology Corp from 2012 to 2025. View PDSB share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.25 Million | $-27.75 Million | -3.000x | -62.74% |
| 2024-12-31 | $19.00 Million | $-35.03 Million | -1.843x | -43.19% |
| 2023-12-31 | $26.13 Million | $-33.64 Million | -1.287x | -120.31% |
| 2022-12-31 | $44.00 Million | $-25.71 Million | -0.584x | -195.79% |
| 2021-12-31 | $63.21 Million | $-12.49 Million | -0.198x | +59.24% |
| 2020-12-31 | $27.13 Million | $-13.15 Million | -0.485x | +68.63% |
| 2019-12-31 | $11.70 Million | $-18.07 Million | -1.545x | -39.06% |
| 2018-12-31 | $29.84 Million | $-33.15 Million | -1.111x | -70.28% |
| 2017-12-31 | $62.37 Million | $-40.70 Million | -0.652x | -80.97% |
| 2016-12-31 | $89.28 Million | $-32.19 Million | -0.361x | -103.01% |
| 2015-12-31 | $122.48 Million | $-21.75 Million | -0.178x | -150.89% |
| 2014-12-31 | $-27.83 Million | $-9.71 Million | 0.349x | -33.40% |
| 2013-12-31 | $-15.35 Million | $-8.04 Million | 0.524x | -21.03% |
| 2012-12-31 | $-3.38 Million | $-2.25 Million | 0.664x | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more